Labcorp Reports $3.81 Billion in Quarterly Revenue
The company saw revenue growth offset by significant acquisition costs during the third quarter.
Updated on Oct. 28, 2026 in Healthcare
Live Poll
Do you believe aggressive corporate acquisitions help or harm the long-term quality of healthcare services?
Labcorp reported third-quarter revenue of $3.81 billion, marking a 6.9% increase. Despite the growth, net income remained flat at $262.8 million as the company absorbed substantial costs related to strategic acquisitions.
Why it matters
The financial results highlight a period of aggressive expansion for Labcorp, which spent $255.5 million on acquisitions to grow its service capabilities. Leadership aims to leverage these investments to expand access to advanced diagnostic testing.
Labcorp reported $3.81 billion in revenue, with $2.95 billion from diagnostics and $866.7 million from biopharma services. Diluted earnings per share reached $3.22, while the company maintains a 72-cent quarterly dividend per share.
The players
Labcorp
A global life sciences company based in Burlington that provides vital health information and diagnostic services.
Myriad Genetics
A genetic testing company based in Salt Lake City that focuses on developing and commercializing diagnostic tests.
MLM Medical Labs
A specialized laboratory services provider with operations in Germany and South Africa.
The details
Labcorp acquired four businesses during the quarter, including MLM Medical Labs, while also launching new tests for advanced melanoma, hepatitis D, and Alzheimer's disease. Operational expenses included $23 million in disposition costs and $28.6 million for the LaunchPad improvement initiative.
Timeline
Sept. 8 marked the closing of the MLM Medical Labs acquisition.
Oct. 20 was the announcement date for the Myriad Genetics agreement.
Nov. 24 serves as the dividend record date for shareholders.
Dec. 11 is the date for the quarterly dividend payment.
Early 2027 is the expected closure date for the Myriad Genetics acquisition.
Market Landscape
Labcorp is actively consolidating the diagnostic laboratory sector through strategic acquisitions to compete with broader healthcare providers. This expansion strategy aligns with the LaunchPad business-process improvement initiative, which seeks to modernize internal operations.
Shareholders are scheduled to receive a quarterly dividend payment of 72 cents per share on Dec. 11. The company's expansion into new diagnostic tests may also lead to increased availability of specialized screenings for patients.
The takeaway
Labcorp remains focused on aggressive growth through high-cost acquisitions despite the immediate impact on net income. Investors and patients should monitor how the integration of these new testing capabilities influences future revenue projections.
What happens next
Labcorp expects to close the acquisition of the Myriad Genetics prenatal business in early 2027.
Further reading
For more on industry trends, visit the Healthcare section.
Source note: This article includes information reported by Greensboro News and Record.
Live Poll
Do you believe aggressive corporate acquisitions help or harm the long-term quality of healthcare services?
